For research use only. Not for therapeutic Use.
Botensilimab (AGEN 1181), a human anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer[1].
Botensilimab has an enhanced Fc region that increases binding to FcγR on antigen presenting cells and natural killer cells[1].
| Catalog Number | I042153 |
| CAS Number | 2408310-37-0 |
| Purity | ≥95% |
| Reference | [1]. Delepine C, et, al. 470 Botensilimab, an Fc-enhanced CTLA-4 antibody, enhances innate and adaptive immune activation to promote superior anti-tumor immunity in cold and I-O refractory tumors FREE. |
